June 2024 – Danish medical cannabis manufacturer Stenocare has announced the launch of a groundbreaking cannabis oil designed to enhance bioavailability. This new product aims to set a higher standard in the medical cannabis industry by improving the body’s absorption of active ingredients, thus increasing the oil’s therapeutic potential. The innovation is expected to address current limitations in cannabis oil products and provide more consistent and effective dosing for patients.

Stenocare’s CEO emphasized that this advancement represents a significant step forward for both the company and the broader medical cannabis community. The new oil, which is now available in select markets, promises to improve patient outcomes by ensuring that a higher percentage of the product’s cannabinoids are absorbed into the bloodstream.

For more details on this innovative product, visit the full article on Business of Cannabis.